...
首页> 外文期刊>Antioxidants and redox signalling >Targeting the Ubiquitin-Proteasome System in Heart Disease: The Basis for New Therapeutic Strategies
【24h】

Targeting the Ubiquitin-Proteasome System in Heart Disease: The Basis for New Therapeutic Strategies

机译:针对心脏病中的泛素-蛋白酶体系统:新治疗策略的基础

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Significance: Novel therapeutic strategies to treat heart failure are greatly needed. The ubiquitin-proteasome system (UPS) affects the structure and function of cardiac cells through targeted degradation of signaling and structural proteins. This review discusses both beneficial and detrimental consequences of modulating the UPS in the heart. Recent Advances: Proteasome inhibitors were first used to test the role of the UPS in cardiac disease phenotypes, indicating therapeutic potential. In early cardiac remodeling and pathological hypertrophy with increased proteasome activities, proteasome inhibition prevented or restricted disease progression and contractile dysfunction. Conversely, enhancing proteasome activities by genetic manipulation, pharmacological intervention, or ischemic preconditioning also improved the outcome of cardiomyopathies and infarcted hearts with impaired cardiac and UPS function, which is, at least in part, caused by oxidative damage. Critical Issues: An understanding of the UPS status and the underlying mechanisms for its potential deregulation in cardiac disease is critical for targeted interventions. Several studies indicate that type and stage of cardiac disease influence the dynamics of UPS regulation in a nonlinear and multifactorial manner. Proteasome inhibitors targeting all proteasome complexes are associated with cardiotoxicity in humans. Furthermore, the type and dosage of proteasome inhibitor impact the pathogenesis in nonuniform ways. Future Directions: Systematic analysis and targeting of individual UPS components with established and innovative tools will unravel and discriminate regulatory mechanisms that contribute to and protect against the progression of cardiac disease. Integrating this knowledge in drug design may reduce adverse effects on the heart as observed in patients treated with proteasome inhibitors against noncardiac diseases, especially cancer. Antioxid. Redox Signal. 21, 2322-2343.
机译:启示:急需治疗心力衰竭的新疗法。泛素-蛋白酶体系统(UPS)通过信号和结构蛋白的定向降解来影响心肌细胞的结构和功能。这篇评论讨论了调节心脏UPS的有益和有害后果。最新进展:蛋白酶体抑制剂首先用于测试UPS在心脏病表型中的作用,表明其治疗潜力。在早期心脏重塑和具有增加的蛋白酶体活性的病理性肥大中,蛋白酶体的抑制阻止或限制了疾病的发展和收缩功能障碍。相反,通过基因操作,药理学干预或局部缺血预处理增强蛋白酶体活性,也可以改善心肌病和心脏和UPS功能受损的梗死心脏的结果,这至少部分是由氧化损伤引起的。关键问题:了解UPS状态及其潜在放松心脏病的潜在机制对于有针对性的干预至关重要。多项研究表明,心脏病的类型和阶段以非线性和多因素的方式影响UPS调节的动态。靶向所有蛋白酶体复合物的蛋白酶体抑制剂与人类心脏毒性有关。此外,蛋白酶体抑制剂的类型和剂量以不均匀的方式影响发病机理。未来方向:使用已建立的和创新的工具,系统地分析和确定单个UPS组件的目标,将阐明和区分有助于和预防心脏病发展的调节机制。将这种知识整合到药物设计中,可以减少对非心脏疾病(尤其是癌症)使用蛋白酶体抑制剂治疗的患者对心脏的不良影响。抗氧化。氧化还原信号。 21,2322-2343。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号